Skip to main content
Signal8
Launch Terminal
THEUER CHARLES profile photo

Charles Theuer

CIK: 0001631338

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (33.3%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

4D Molecular Therapeutics, Inc. logo
FDMT

4D Molecular Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • 4D Molecular Therapeutics, Inc. logo
    FDMT

    4D Molecular Therapeutics, Inc.

    Jun 17, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    50K shares-
  • 4D Molecular Therapeutics, Inc. logo
    FDMT

    4D Molecular Therapeutics, Inc.

    Dec 12, 2025
    Exercise(M)
    Direct
    9.3K shares at avg. $1.14$11K
  • 4D Molecular Therapeutics, Inc. logo
    FDMT

    4D Molecular Therapeutics, Inc.

    Jun 17, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    22.5K shares-

1-3 of 3

About THEUER CHARLES

THEUER CHARLES (SEC CIK 0001631338) files insider reports with the SEC as Director of 4D Molecular Therapeutics, Inc. (FDMT).

Signal8 holds 3 ownership filings by THEUER CHARLES, all Form 4s, filed between Jun 20, 2025 and Jun 18, 2026. Those filings report 3 transactions, from Jun 17, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on THEUER CHARLES's filings is in EMERYVILLE, CA.

Recent filings by THEUER CHARLES

  • Jun 17, 2026: Grant or award of FDMT derivative securities (Form 4, code A).
  • Dec 12, 2025: Option exercise of FDMT shares (Form 4, code M).
  • Jun 17, 2025: Grant or award of FDMT derivative securities (Form 4, code A).

Other insiders filing for 4D Molecular Therapeutics, Inc. (FDMT)

How to read Form 4 transaction codes